RHABDOMYOSARCOMA
Clinical trials for RHABDOMYOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new RHABDOMYOSARCOMA trials appear
Sign up with your email to follow new studies for RHABDOMYOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with resistant cancers: targeted drug enters trial
Disease control Not yet recruitingThis study tests a drug called ifinatamab deruxtecan (I-DXd) in children with solid tumors that have returned or not responded to treatment. The drug is an antibody-drug conjugate that targets cancer cells directly. The trial aims to check safety and see if tumors shrink in about…
Matched conditions: RHABDOMYOSARCOMA
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New trial seeks best chemo strategy for childhood muscle cancer
Disease control Not yet recruitingThis study compares two chemotherapy plans for people with newly diagnosed intermediate-risk rhabdomyosarcoma, a type of muscle cancer. One group gets a higher dose of chemo over a shorter time, while the other gets a lower dose over a longer time plus extra maintenance drugs. Th…
Matched conditions: RHABDOMYOSARCOMA
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug cocktail takes on rare nerve tumors
Disease control Not yet recruitingThis early-phase trial tests a combination of three drugs—selumetinib, ZEN-3694, and durvalumab—in people with advanced sarcomas, including malignant peripheral nerve sheath tumors (MPNST) linked to NF1. The study first checks safety and dosing, then looks at whether the treatmen…
Matched conditions: RHABDOMYOSARCOMA
Phase: PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Hope for rhabdomyosarcoma: vitamin a derivative joins chemo in new trial
Disease control Not yet recruitingThis Phase 2 trial tests whether adding all-trans retinoic acid (a vitamin A derivative) to standard VAC chemotherapy improves outcomes for 106 people aged 14-60 with intermediate-to-high-risk rhabdomyosarcoma, a rare muscle cancer. Participants will receive the drug combo in 21-…
Matched conditions: RHABDOMYOSARCOMA
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests a new treatment for adults with solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein called GPC3. The…
Matched conditions: RHABDOMYOSARCOMA
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Light therapy may shield kids with cancer from chemo mouth sores
Prevention Not yet recruitingThis study tests whether light therapy (photobiomodulation) can prevent mouth sores in children receiving chemotherapy. Fifty children aged 0-30 will receive daily light treatments during hospital stays and at home. Researchers will check if the therapy is easy to use and accepta…
Matched conditions: RHABDOMYOSARCOMA
Phase: NA • Sponsor: Medical College of Wisconsin • Aim: Prevention
Last updated Jun 27, 2026 14:01 UTC
-
Weekly scans may make proton therapy safer for kids with cancer
Knowledge-focused Not yet recruitingThis study will enroll 100 children with solid tumors or Hodgkin lymphoma who are receiving proton therapy. Researchers will take weekly or bi-weekly CT or MRI scans during treatment to check if the original radiation plan is still accurate. If tumor coverage drops by 5% or radia…
Matched conditions: RHABDOMYOSARCOMA
Phase: NA • Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New app guides young cancer survivors through life after treatment
Knowledge-focused Not yet recruitingThis study is testing a mobile app called my.naviGATE for teens and young adults (ages 15-24) who have finished cancer treatment. The app provides personalized education, peer support, and tracks how patients are doing. Researchers want to see if the app helps patients feel more …
Matched conditions: RHABDOMYOSARCOMA
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC